FluoroPharma Medical, Inc., a company specializing in the development of breakthrough diagnostic imaging products that utilize positron emission tomography (PET) technology to detect and assess pathology before clinical manifestation of diseases, announced this morning that they have secured an additional $1.010 million, bringing the total to more than $7 million over the course of 2011 from institutional and accredited investors.
“We are excited by the opportunities this additional working capital creates for FluoroPharma to significantly accelerate development of our pipeline,” stated Thijs Spoor, FluoroPharma’s President and CEO. “The funding will allow us to further advance our most promising portfolio of diagnostic imaging products, providing healthcare professionals with new products that expand and improve their diagnostic capabilities and contribute to earlier, more accurate diagnosis and treatment of disease– even before symptoms appear.”
Dr. David Elmaleh, Chairman of FluoroPharma’s Board of Directors added, “We are pleased that we have the resources to advance our clinical plans and achieve significant development milestones.”
Further details of the additional funds raised are available in the company’s most recent 8k.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
